Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once yearly dosing in spinal muscular atrophy (SMA) Interim Phase 1 data show ...
Biogen Inc. announced positive interim results from a Phase 1 study of salanersen (BIIB115/ION306), a novel antisense oligonucleotide for treating spinal muscular atrophy (SMA). The data show that ...
Advancements in peptide and oligonucleotide synthesis via precision chemistry are transforming therapeutic development by ...
Biogen has pointed to an early readout from a small phase 1 trial as evidence that its antisense oligonucleotide salanersen could help children with spinal muscular atrophy (SMA) who are still ...
CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BIIB080, an ...
DUBLIN--(BUSINESS WIRE)--The "Oligonucleotide Synthesis Market: Forecast by Oligo Length, Application, Category, Type, Product, and Region, with Executive and Consultant Guides" report has been added ...
(MENAFN- GlobeNewsWire - Nasdaq) Delray Beach, FL, Feb. 16, 2026 (GLOBE NEWSWIRE) -- Strategic investments in ASO and siRNA platforms, coupled with breakthrough delivery technologies, position ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results